📢 Gate Square #MBG Posting Challenge# is Live— Post for MBG Rewards!
Want a share of 1,000 MBG? Get involved now—show your insights and real participation to become an MBG promoter!
💰 20 top posts will each win 50 MBG!
How to Participate:
1️⃣ Research the MBG project
Share your in-depth views on MBG’s fundamentals, community governance, development goals, and tokenomics, etc.
2️⃣ Join and share your real experience
Take part in MBG activities (CandyDrop, Launchpool, or spot trading), and post your screenshots, earnings, or step-by-step tutorials. Content can include profits, beginner-friendl
Novo Nordisk: 7.2mg semaglutide phase 3 clinical trial met the primary endpoint with a weight loss of 20.7% at 72 weeks.
On January 18, Jins data reported that on January 17 local time, Novo Nordisk announced the main results of the 3b phase clinical trial STEP UP. In the STEP UP obesity trial, subcutaneous injection of 7.2mg semaglutide once a week resulted in a weight loss of 20.7% at 72 weeks, and a weight loss of 18.7% regardless of treatment compliance. The trial met its primary endpoint, with 7.2mg semaglutide showing statistically significant and superior weight loss compared to placebo at 72 weeks.